Therapy of disseminated colorectal cancer: The emerging role of intratumoral molecular biology

European Journal of Surgery, Supplement

Volumn 167, Issue 586, 2001, Pages 43-48

  Leichman, L ^a   Leichman, C G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; COMPLEMENTARY DNA; DEOXYURIDINE PHOSPHATE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; THYMIDINE; THYMIDINE PHOSPHATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; THYMINE; OXIDOREDUCTASE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; TREATMENT FAILURE; TUMOR BIOPSY; COLORECTAL TUMOR; ENZYMOLOGY; REVIEW;

COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; OXIDOREDUCTASES; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 0034740539     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells
2. Mechanisms and therapeutic implications of angiogenesis
3. CPT-11 in gastrointestinal cancer
4. Adjuvant cyclophosphamnide, methotrexate, and fluorouracil (CMF) in node positive breast cancer: The results of 20 years of follow-up
5. Topoisomerase I inhibitors: An overview of the camptothecin analogs
6. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC)
7. Unstable methotrexate resistance in human small cell carcinoma associated with double minute chromosomes
8. Thymidylate synthase (TS) and thymidine phosphorylase (TP) are prognostic indicators of survival for colorectal cancer
9. Dihydropyrimidine Dehydrogenase (DPD) and Thymidylate Synthase (TS) gene expressions identify a high percentage of colorectal tumors responding to 5-Fluorouracil (5-FU)
10. Survival after postoperative combination treatment of rectal cancer
11. The polymerase chain reaction: A new method of using molecular genetics for medical diagnosis
12. Enhancement of 5-fluorouracil cytotoxicity by human thymidine phosphorylase expression in cancer cells: In vitro and in vivo study
13. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas due to the effects of adjuvant CMF
14. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epethelium and endothelium
15. Platelet derived endothelial cell growth factor (thymidine phosphoryoase) expression in lung cancer
16. Fluorininated pyrimidines. A new class of tumor inhibitory compounds
17. Studies on fluroinated pyrimidines II. Effects on transplanted tumors
18. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
19. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in human cancer xenografts
20. Xeloda™ (capecitabine): An orally available tumor-selective fluoropyrimidine carbamate
21. Thymidylate synthase and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
22. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
23. Platelet-derived endothelial cell growth factor expression correlates with tumor angiogenesis and prognosis in non-small cell lung cancer
24. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion 5-fluorouracil and weekly leucovorin
25. Pyrimidine nucleotide metabolism in human colon carcinomas: Comparison of normal tissues, primary tumors and xenografts
26. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity
27. The mechanism of cytotoxic action of 5-fluoro-2′-deoxyuridine in thymidine phophorylase expressing cell lines
28. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
29. Thymidine phosphorylase is angiogenic and promotes tumor growth
30. Enzymes of uracil catabolism in normal and neoplastic human tissues
31. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
32. Inactivation of dihydropyrimidine dehydrogenase in vivo
33. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
34. High Thymidylate Synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC)
35. Tumor selectivity of Xeloda™ in colorectal cancer patients
36. Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer
37. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
38. Expression of thymidine phosphorylase in human gastric carcinoma
39. The activity and expression of thymidine phosphorylase in human solid tumors
40. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy
41. Epidermoid anal cancer: Results from the UKCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitmycin
42. A comparison of multimodal therapy and surgery for esophageal adenocarcionoma
43. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity
44. Preclinical and phase I trials of topoisomerase I inhibitors